Newron’s Schizophrenia Candidate Gets Better Over Time

Newron’s Schizophrenia Candidate Gets Better Over Time

Source: 
BioSpace
snippet: 

One-year interim data from a Phase II study of Newron Pharmaceuticals’ schizophrenia candidate evenamide showed sustained efficacy and continued improvements in symptoms of psychosis and disease severity, the Milan-based company reported Thursday.